Table 1.
Demographics of Study Sample by Calendar Year
| No. (%) of Patients by Calendar Year
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2001 (n = 5445) | 2002 (n = 6433) | 2003 (n = 8287) | 2004 (n = 9537) | 2005 (n = 10 137) | 2006 (n = 11 030) | 2007 (n = 12 194) | 2008 (n = 13 719) | 2009 (n = 14 684) | 2010 (n = 15 944) | |
| Age group, y | ||||||||||
| 18–29 | 729 (13.4) | 869 (13.5) | 1012 (12.7) | 1212 (12.7) | 1171 (11.6) | 1269 (11.5) | 1343 (11.0) | 1536 (11.2) | 1754 (11.9) | 1977 (12.4)b |
|
| ||||||||||
| 30–39 | 2214 (40.7) | 2436 (37.9) | 2950 (35.6) | 3164 (33.2) | 3035 (29.9) | 3009 (27.3) | 3081 (25.3) | 3263 (23.8) | 3316 (22.6) | 3434 (21.5) |
|
| ||||||||||
| 40–49 | 1782 (32.7) | 2200 (34.2) | 3032 (36.6) | 3523 (36.9) | 3930 (38.8) | 4322 (39.2) | 4857 (39.8) | 5382 (39.2) | 5624 (38.3) | 5871 (36.8) |
|
| ||||||||||
| ≥50 | 720 (13.2) | 928 (14.4) | 1292 (15.6) | 1638 (17.2) | 2001 (19.7) | 2430 (22.0) | 2913 (23.9) | 3537 (25.8) | 3990 (27.2) | 4662 (29.2) |
|
| ||||||||||
| Sex | ||||||||||
| Male | 3776 (69.3) | 4602 (71.6) | 5879 (71.0) | 6721 (70.5) | 7167 (70.7) | 7731 (70.1) | 8562 (70.2) | 9568 (69.7) | 10 337 (70.4) | 11 339 (71.1) |
|
| ||||||||||
| Female | 1669 (30.7) | 1830 (28.4) | 2407 (29.0) | 2816 (29.5) | 2970 (29.3) | 3299 (29.9) | 3632 (29.8) | 4151 (30.3) | 4347 (29.6) | 4605 (28.9) |
|
| ||||||||||
| Race/ethnicity | ||||||||||
| White | 1379 (25.3) | 1757 (27.3) | 2294 (27.7) | 2599 (27.3) | 2672 (26.4) | 2748 (24.9) | 3005 (24.6) | 3250 (23.7) | 3449 (23.5) | 3705 (23.2)b |
|
| ||||||||||
| Black | 2658 (48.8) | 3163 (49.2) | 4039 (48.7) | 4637 (48.6) | 4944 (48.8) | 5535 (50.2) | 6099 (50.0) | 6977 (50.9) | 7464 (50.8) | 8164 (51.1) |
|
| ||||||||||
| Hispanic | 1295 (23.8) | 1358 (21.1) | 1786 (21.6) | 2106 (22.1) | 2258 (22.3) | 2406 (21.8) | 2726 (22.4) | 3106 (22.6) | 3336 (22.7) | 3548 (22.3) |
|
| ||||||||||
| HIV risk factor | ||||||||||
| MSM | 1804 (33.1) | 2397 (37.3) | 3132 (37.8) | 3570 (37.4) | 3866 (38.1) | 4207 (38.1) | 4666 (38.3) | 5145 (37.5) | 5742 (39.1) | 6377 (40.0)b |
|
| ||||||||||
| HET | 2072 (38.1) | 2308 (35.8) | 3140 (37.9) | 3756 (39.4) | 4056 (40.0) | 4583 (41.6) | 5033 (41.3) | 5700 (41.6) | 6110 (41.6) | 6518 (40.9) |
|
| ||||||||||
| IDU | 1290 (23.7) | 1349 (21.0) | 1617 (19.5) | 1737 (18.2) | 1750 (17.3) | 1832 (16.6) | 1993 (16.4) | 2208 (16.1) | 2158 (14.7) | 2175 (13.6) |
|
| ||||||||||
| Insurance | ||||||||||
| Private | 642 (11.8) | 825 (12.8) | 757 (9.1) | 905 (9.5) | 1317 (13.0) | 1440 (13.1) | 1835 (15.1) | 2028 (14.8) | 2105 (14.3) | 2695 (17.3)b |
|
| ||||||||||
| Medicaid | 2353 (43.2) | 2390 (37.2) | 2824 (34.1) | 2956 (31.0) | 3849 (38.0) | 3957 (35.9) | 4330 (35.5) | 5225 (38.1) | 5396 (36.8) | 5075 (32.5) |
|
| ||||||||||
| Medicare | 425 (7.8) | 545 (8.5) | 762 (9.2) | 903 (9.5) | 1118 (11.0) | 1667 (15.1) | 1812 (14.9) | 2097 (15.3) | 2287 (15.6) | 2690 (17.3) |
|
| ||||||||||
| Uninsured | 1823 (33.5) | 2181 (33.9) | 2816 (34.0) | 3073 (32.2) | 3276 (32.3) | 3577 (32.4) | 3674 (30.1) | 3836 (28.0) | 4204 (28.6) | 4711 (30.2) |
|
| ||||||||||
| CD4 T-cell count, /μL | ||||||||||
| ≤200 | 1653 (30.4) | 1711 (26.6) | 2062 (24.9) | 2271 (23.8) | 2357 (23.3) | 2382 (21.6) | 2515 (20.6) | 2767 (20.2) | 2728 (18.6) | 2674 (16.8) |
|
| ||||||||||
| >200 | 3792 (69.6) | 4722 (73.4) | 6224 (75.1) | 7266 (76.2) | 7780 (76.8) | 8648 (78.4) | 9679 (79.4) | 10 952 (79.8) | 11 956 (81.4) | 13 270 (83.2) |
|
| ||||||||||
| Receiving ART | ||||||||||
| Recommendedc | 1596 (77.6) | 1752 (79.2) | 2166 (77.2) | 2280 (77.5) | 2475 (80.9) | 2498 (81.7) | 4956 (80.9) | 5905 (85.5) | 6320 (89.9) | 6313 (91.3)b |
|
| ||||||||||
| All | 3597 (66.1) | 4340 (67.5) | 5490 (66.3) | 6254 (66.0) | 6887 (69.2) | 7769 (72.0) | 8773 (74.9) | 10 609 (79.3) | 11 980 (83.7) | 13 372 (86.3)b |
|
| ||||||||||
| HIV RNA ≤400 copies/mLd | 1008 (44.7) | 1432 (44.9) | 1895 (45.8) | 2543 (51.5) | 3146 (55.2) | 3831 (58.6) | 4358 (60.5) | 5591 (63.8) | 6852 (68.6) | 8061 (72.2)b |
Abbreviations: ART, antiretroviral therapy; HET, heterosexual transmission; HIV, human immunodeficiency virus; IDU, injection drug use; MSM, men who have sex with men.
Median follow-up time of care for the cohort was 2 years (mean, 3.3 years). The number of patients receiving care was defined as attending 1 or more clinic visit and having 1 or more CD4 test recorded during the year.
For test of association between row variable and year (2001–2010), the P value was less than .05.
Among patients recommended to receive ART: CD4 T-cell count of 200/μL or less for 2001–2006; CD4 T-cell count of 350/μL or less for 2007–2010.
Among all patients receiving ART; median number of HIV RNA tests per patient per year was 2 for 2001 and 3 for 2002–2010.